Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. reports a corporate governance event that occurred on December 17, 2014, with the report filed on December 18, 2014. The filing addresses the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size from nine to ten members.
- New Appointment: Michael W. Bonney was elected to fill the newly created vacancy as a Class I director, with a term expiring at the 2017 annual meeting of stockholders.
- Compensation: Mr. Bonney received a stock option to purchase 30,000 shares of common stock, vesting annually over three years. He will also receive standard director compensation as outlined in the company's 2014 Proxy Statement.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the disclosure of the director's appointment and associated compensatory arrangements.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 30,000 stock options granted to Michael W. Bonney.
- Review the Company's Proxy Statement for the 2014 Annual Meeting to confirm the specific cash compensation policy for non-employee directors.
- Confirm the background and qualifications of the newly elected director, Michael W. Bonney.